VEGF-inhibitor thrombotic microangiopathy

The pathophysiology as a cascade — select a step to follow the mechanism.

1. 2003

   Eremina and Quaggin engineer podocyte-specific VEGF-A gene-dosage mice: losing one podocyte VEGF allele produces proteinuria and glomerular endotheliosis (the preeclampsia lesion), while VEGF overexpression yields collapsing glomerulopathy.

   Established that podocyte-derived VEGF-A is exquisitely dose-sensitive and maintains the glomerular filtration barrier — the conceptual foundation for how blocking VEGF could injure the kidney.

   PMID 12618525
2. 2007

   Zhu, Wu, and colleagues publish the first systematic review and meta-analysis quantifying the renal signal of bevacizumab across randomized trials.

   Turned scattered trial toxicity tables into a hard, dose-dependent risk estimate for proteinuria and hypertension, putting anti-VEGF renal injury on the map as a class effect.

   PMID 17261421
3. 2008

   Eremina et al. report six bevacizumab-treated patients with biopsy-proven glomerular thrombotic microangiopathy AND delete VEGF from adult mouse podocytes, reproducing profound thrombotic glomerular injury.

   The landmark bench-to-bedside paper proving direct causation: local podocyte VEGF withdrawal is sufficient to trigger renal TMA in humans on anti-VEGF therapy.

   PMID 18337603
4. 2010

   Wu et al. pool 16 trials and 12,268 patients to quantify severe (grade 3-4) proteinuria, nephrotic syndrome, and tumor-specific risk with bevacizumab.

   Defined the magnitude and risk stratification of the severe end of the spectrum, flagging renal cell carcinoma as the highest-risk setting.

   PMID 20538785
5. 2013

   Izzedine et al. biopsy 29 patients on VEGF-targeted therapy and separate two distinct lesions — thrombotic microangiopathy (mostly with anti-VEGF antibodies) versus minimal-change/FSGS-like disease (mostly with receptor TKIs), with normal ADAMTS13 and no complement-gene mutations.

   Reframed 'VEGF-inhibitor nephrotoxicity' as at least two mechanistically different entities and showed anti-VEGF TMA is not classic TTP or genetic aHUS.

   PMID 24067439
6. 2016

   Keir et al. show VEGF blockade lowers locally produced inhibitory complement factor H in the eye and kidney via reduced VEGFR2/PKC-alpha/CREB signaling, amplifying alternative-pathway deposition on cells carrying CFH risk variants.

   Provided a mechanistic bridge between VEGF withdrawal and complement dysregulation, explaining why a minority of patients tip into severe, complement-flavored TMA.

   PMID 27918307
7. 2019

   Estrada, Mallipattu and colleagues synthesize the field into a mechanism-based map of VEGF-pathway nephrotoxicities in JASN.

   Consolidated the drug-class-to-lesion logic (direct VEGF/VEGF-trap blockade → renal-limited TMA; receptor TKIs → podocytopathy) that now guides clinical reasoning.

   PMID 30642877

1. 1

   Withdraw or hold the offending anti-VEGF agent

   Discontinuation is the cornerstone: proteinuria typically declines and TMA lesions can stabilize or regress, though proteinuria may persist and full recovery can lag months behind withdrawal. Decisions are individualized against oncologic benefit.

   Observational case series and reviews (no randomized data); consistent signal across cohorts · PMID 39879682

2. 2

   Blood-pressure control with RAAS blockade (ACE inhibitor or ARB)

   ACE inhibitors/ARBs are generally preferred because they lower blood pressure and are antiproteinuric, though no controlled trial has established a specific antiproteinuric agent in this setting.

   Expert opinion / narrative review; no controlled trials · PMID 20006922

3. 3

   Structured monitoring and grading-based dose modification

   Baseline and periodic urine protein (dipstick or protein/creatinine ratio) and blood pressure; hold therapy for grade 3+ proteinuria or nephrotic syndrome and refer to nephrology, given the demonstrated dose-dependence of severe proteinuria.

   Meta-analytic risk data plus review-based practice guidance · PMID 20538785

4. 4

   Distinguish from TTP/aHUS before reaching for plasma exchange

   Check ADAMTS13 (preserved in anti-VEGF TMA) and consider that complement regulatory genes are typically normal; plasma exchange, effective in TTP, is generally not indicated for drug-induced anti-VEGF TMA.

   Clinicopathologic case series with mechanistic testing · PMID 24067439

5. 5

   Complement (C5) blockade reserved for severe, systemic, or refractory TMA

   Terminal complement inhibition is anecdotal and controversial here — biologically rationalized by reduced local factor H after VEGF blockade, but most anti-VEGF TMA lacks the complement-gene mutations of aHUS, so it is a case-by-case consideration, not routine care.

   Mechanistic/translational rationale plus anecdotal reports; not standard of care · PMID 27918307

Society and consensus recommendations addressing this syndrome, each with its key recommendation quoted verbatim.

Drug-induced TMA is a diagnosis of pattern and exclusion. Narrow the differential first, then estimate the pretest probability of TTP before committing to plasma exchange.